Suppr超能文献

胰高血糖素样肽对肠道乳糜微粒生成的调节

Regulation of intestinal chylomicron production by glucagon-like peptides.

作者信息

Hsieh Joanne, Adeli Khosrow

机构信息

Molecular Structure and Function, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.

出版信息

Cardiovasc Hematol Disord Drug Targets. 2012 Dec;12(2):92-7. doi: 10.2174/1871529x11202020092.

Abstract

Apolipoprotein B48 (apoB48)-containing triglyceride-rich lipoproteins are atherogenic and therefore it is important to understand factors that regulate their metabolism in the intestine. Insulin resistant states are associated with increased intestinal output of apo B48, but the mechanistic studies explaining this overproduction have relied heavily on models of diet-induced insulin resistance. There is evidence that glucagon-like peptide (GLP) secretion is diminished in insulin resistant and diabetic states, which may have implications for postprandial lipid secretion. This review presents a survey of studies on GLPs and intestinal lipoprotein metabolism, along with some insights into the net physiological significance of GLP action in postprandial lipoprotein metabolism. Studies with GLP-1 receptor agonists and dipeptidyl peptidase-IV inhibitors have indicated that GLP-1 in pharmacological and physiological doses can inhibit intestinal TRL production. On the other hand, GLP-2 has an acute stimulatory effect on intestinal apoB48 secretion. Modulating GLP action may serve as a strategy to improve postprandial dyslipidemia in insulin resistant states.

摘要

含载脂蛋白B48(apoB48)的富含甘油三酯的脂蛋白具有致动脉粥样硬化作用,因此了解调节其在肠道中代谢的因素很重要。胰岛素抵抗状态与apo B48肠道输出增加有关,但解释这种过量产生的机制研究严重依赖于饮食诱导的胰岛素抵抗模型。有证据表明,在胰岛素抵抗和糖尿病状态下,胰高血糖素样肽(GLP)分泌减少,这可能对餐后脂质分泌有影响。本文综述了有关GLP与肠道脂蛋白代谢的研究概况,并对GLP作用在餐后脂蛋白代谢中的净生理意义进行了一些探讨。使用GLP-1受体激动剂和二肽基肽酶-IV抑制剂的研究表明,药理和生理剂量的GLP-1可抑制肠道富含甘油三酯脂蛋白(TRL)的产生。另一方面,GLP-2对肠道apoB48分泌有急性刺激作用。调节GLP作用可能是改善胰岛素抵抗状态下餐后血脂异常的一种策略。

相似文献

1
Regulation of intestinal chylomicron production by glucagon-like peptides.
Cardiovasc Hematol Disord Drug Targets. 2012 Dec;12(2):92-7. doi: 10.2174/1871529x11202020092.
2
New and emerging regulators of intestinal lipoprotein secretion.
Atherosclerosis. 2014 Apr;233(2):608-615. doi: 10.1016/j.atherosclerosis.2013.12.047. Epub 2014 Jan 21.
5
Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.
Arterioscler Thromb Vasc Biol. 2015 May;35(5):1092-100. doi: 10.1161/ATVBAHA.114.304873. Epub 2015 Feb 12.
6
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
Gastroenterology. 2009 Sep;137(3):997-1005, 1005.e1-4. doi: 10.1053/j.gastro.2009.05.051. Epub 2009 May 29.
7
Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.
Cardiovasc Hematol Disord Drug Targets. 2014;14(2):126-36. doi: 10.2174/1871529x14666140505125300.
8
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
Curr Opin Lipidol. 2012 Feb;23(1):56-61. doi: 10.1097/MOL.0b013e32834d68f0.
9
Intestinal lipid absorption and transport in type 2 diabetes.
Diabetologia. 2022 Oct;65(10):1587-1600. doi: 10.1007/s00125-022-05765-8. Epub 2022 Jul 30.

引用本文的文献

1
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.
Nat Rev Cardiol. 2022 Sep;19(9):577-592. doi: 10.1038/s41569-022-00676-y. Epub 2022 Mar 22.
2
Semaglutide seems to be more effective the other GLP-1Ras.
Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验